Abstract
RNA is a versatile molecule that performs myriad roles in the cells. The differential expression of RNA is both indicative and causative for many pathological conditions, including cancer. Comprehensive studies over the past decade have been instrumental in highlighting the tissue-specific expression and dysregulation of ncRNA expression and function in cancers of different origins. While the miRNAs have been thoroughly studied and their targets verified, the contribution of other small and long ncRNAs in the field of cancer biology needs further exploration and validation. RNA-based therapeutics, though an exciting field, is still in its infancy, and there are many issues to be addressed before it reaches the clinics. In this chapter we will discuss the use of ncRNAs as diagnostic and prognostic biomarkers in different types of cancer. We further discuss their contribution to intrinsic and acquired chemoresistance of cancer cells and strategies for modulating the abundance and functions of both coding and non-coding RNAs in vivo. We also deliberate over the challenges and recent platforms for the delivery of therapeutic RNAs to the target site.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akerman ME, Chan WCW, Laakkonen P et al (2002) Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99:12617–12621. https://doi.org/10.1073/pnas.152463399
Albertazzi L, Mickler FM, Pavan GM et al (2012) Enhanced bioactivity of internally functionalized cationic dendrimers with PEG cores. Biomacromolecules 13:4089–4097. https://doi.org/10.1021/bm301384y
Alegre E, Sanmamed MF, Rodriguez C et al (2014) Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 138:828–832. https://doi.org/10.5858/arpa.2013-0134-OA
André EM, Passirani C, Seijo B et al (2016) Nano and microcarriers to improve stem cell behaviour for neuroregenerative medicine strategies: application to Huntington’s disease. Biomaterials 83:347–362. https://doi.org/10.1016/j.biomaterials.2015.12.008
Arroyo JD, Chevillet JR, Kroh EM et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008. https://doi.org/10.1073/pnas.1019055108
Aryani A, Denecke B (2016) Exosomes as a nanodelivery system: a key to the future of neuromedicine? Mol Neurobiol 53:818–834. https://doi.org/10.1007/s12035-014-9054-5
Bader AG, Brown D, Stoudemire J, Lammers P (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18:1121–1126. https://doi.org/10.1038/gt.2011.79
Bak RO, Mikkelsen JG (2014) miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA 5:317–333. https://doi.org/10.1002/wrna.1213
Bak RO, Hollensen AK, Primo MN et al (2013) Potent microRNA suppression by RNA Pol II-transcribed “Tough Decoy” inhibitors. RNA 19:280–293. https://doi.org/10.1261/rna.034850.112
Balazs DA, Godbey W (2011) Liposomes for use in gene delivery. J Drug Deliv 2011. https://doi.org/10.1155/2011/326497
Bao L, Hazari S, Mehra S et al (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180:2490–2503. https://doi.org/10.1016/j.ajpath.2012.02.024
Bartlett DW, Davis ME (2006) Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 34:322–333. https://doi.org/10.1093/nar/gkj439
Bartlett DW, Davis ME (2007) Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 97:909–921. https://doi.org/10.1002/bit.21285
Bartlett DW, Su H, Hildebrandt IJ et al (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 104:15549–15554. https://doi.org/10.1073/pnas.0707461104
Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14:1122–1132. https://doi.org/10.1021/bc034125f
Bennett MJ, Nantz MH, Balasubramaniam RP et al (1995) Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells. Biosci Rep 15:47–53
Berezhnoy A, Castro I, Levay A et al (2014) Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest 124:188–197. https://doi.org/10.1172/JCI69856
Bernardo BC, Gao X-M, Winbanks CE et al (2012) Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 109:17615–17620. https://doi.org/10.1073/pnas.1206432109
Berrondo C, Flax J, Kucherov V et al (2016) Expression of the long non-coding RNA HOTAIR correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One 11:e0147236. https://doi.org/10.1371/journal.pone.0147236
Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465–472
Boden D, Pusch O, Lee F et al (2003) Promoter choice affects the potency of HIV-1 specific RNA interference. Nucleic Acids Res 31:5033–5038
Broderick JA, Zamore PD (2011) MicroRNA therapeutics. Gene Ther 18:1104–1110. https://doi.org/10.1038/gt.2011.50
Brown BD, Gentner B, Cantore A et al (2007) Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25:1457–1467. https://doi.org/10.1038/nbt1372
Bryant RJ, Pawlowski T, Catto JWF et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. https://doi.org/10.1038/bjc.2011.595
Burris HA, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405. https://doi.org/10.1200/JCO.2010.29.5865
Campani V, Salzano G, Lusa S, De Rosa G (2016) Lipid nanovectors to deliver RNA oligonucleotides in cancer. Nanomaterials 6. https://doi.org/10.3390/nano6070131
Cazzoli R, Buttitta F, Di Nicola M et al (2013) microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol 8:1156–1162. https://doi.org/10.1097/JTO.0b013e318299ac32
Cerchia L, de Franciscis V (2010) Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28:517–525. https://doi.org/10.1016/j.tibtech.2010.07.005
Chandra Gupta S, Nandan Tripathi Y (2017) Potential of long non-coding RNAs in cancer patients: from biomarkers to therapeutic targets. Int J Cancer 140:1955–1967. https://doi.org/10.1002/ijc.30546
Chen CY, Shyu AB (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20:465–470
Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006. https://doi.org/10.1038/cr.2008.282
Chen Y, Gao D-Y, Huang L (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev 81:128–141. https://doi.org/10.1016/j.addr.2014.05.009
Cheng G (2015) Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 81:75–93. https://doi.org/10.1016/j.addr.2014.09.001
Chi KN, Hotte SJ, Yu EY et al (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28:4247–4254. https://doi.org/10.1200/JCO.2009.26.8771
Chitkara D, Singh S, Mittal A (2016) Nanocarrier-based co-delivery of small molecules and siRNA/miRNA for treatment of cancer. Ther Deliv 7:245–255. https://doi.org/10.4155/tde-2015-0003
Citti L, Rainaldi G (2005) Synthetic hammerhead ribozymes as therapeutic tools to control disease genes. Curr Gene Ther 5:11–24
Conry RM, LoBuglio AF, Wright M et al (1995) Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 55:1397–1400
Costa PM, Cardoso AL, Custódia C et al (2015) MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: a new multimodal gene therapy approach for glioblastoma. J Control Release 207:31–39. https://doi.org/10.1016/j.jconrel.2015.04.002
Darfeuille F, Reigadas S, Hansen JB et al (2006) Aptamers targeted to an RNA hairpin show improved specificity compared to that of complementary oligonucleotides. Biochemistry (Mosc) 45:12076–12082. https://doi.org/10.1021/bi0606344
Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6:659–668. https://doi.org/10.1021/mp900015y
Davis ME, Zuckerman JE, Choi CHJ et al (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1070. https://doi.org/10.1038/nature08956
Deras IL, Aubin SMJ, Blase A et al (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587–1592. https://doi.org/10.1016/j.juro.2007.11.038
Doench JG, Petersen CP, Sharp PA (2003) siRNAs can function as miRNAs. Genes Dev 17:438–442. https://doi.org/10.1101/gad.1064703
Dong Y, Zhao J, Wu C-W et al (2013) Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res MCR 11:1051–1060. https://doi.org/10.1158/1541-7786.MCR-13-0061
Donzelli S, Mori F, Biagioni F et al (2014) MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther 2:16. https://doi.org/10.1186/2052-8426-2-16
Du Y, Kong G, You X et al (2012) Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287:26302–26311. https://doi.org/10.1074/jbc.M112.342113
Ebert MS, Sharp PA (2010) MicroRNA sponges: progress and possibilities. RNA 16:2043–2050. https://doi.org/10.1261/rna.2414110
Eblen ST (2012) Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol 83:1063–1072. https://doi.org/10.1016/j.bcp.2011.12.041
Eichelser C, Stückrath I, Müller V et al (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 5:9650–9663. https://doi.org/10.18632/oncotarget.2520
El-Andaloussi S, Järver P, Johansson HJ, Langel U (2007) Cargo-dependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 407:285–292. https://doi.org/10.1042/BJ20070507
Ernsting MJ, Murakami M, Roy A, Li S-D (2013) Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release 172:782–794. https://doi.org/10.1016/j.jconrel.2013.09.013
Esposito T, Magliocca S, Formicola D, Gianfrancesco F (2011) piR_015520 belongs to Piwi-associated RNAs regulates expression of the human melatonin receptor 1A gene. PLoS One 6:e22727. https://doi.org/10.1371/journal.pone.0022727
Forman JJ, Coller HA (2010) The code within the code: microRNAs target coding regions. Cell Cycle Georget Tex 9:1533–1541. https://doi.org/10.4161/cc.9.8.11202
Frampton AE, Castellano L, Colombo T et al (2014) MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 146:268–277.e18. https://doi.org/10.1053/j.gastro.2013.10.010
Gentner B, Schira G, Giustacchini A et al (2009) Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6:63–66. https://doi.org/10.1038/nmeth.1277
Gerber DE (2008) Targeted therapies: a new generation of cancer treatments. Am Fam Physician 77:311–319
Gumireddy K, Young DD, Xiong X et al (2008) Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Eng 47:7482–7484. https://doi.org/10.1002/anie.200801555
Gupta RA, Shah N, Wang KC et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071–1076. https://doi.org/10.1038/nature08975
Han Li C, Chen Y (2015) Small and long non-coding RNAs: novel targets in perspective cancer therapy. Curr Genomics 16:319–326. https://doi.org/10.2174/1389202916666150707155851
Hang Q, Sun R, Jiang C, Li Y (2015) Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. Anti-Cancer Drugs 26:632–640. https://doi.org/10.1097/CAD.0000000000000227
Hanini A, Schmitt A, Kacem K et al (2011) Evaluation of iron oxide nanoparticle biocompatibility. Int J Nanomedicine 6:787–794. https://doi.org/10.2147/IJN.S17574
Hanke M, Hoefig K, Merz H et al (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661. https://doi.org/10.1016/j.urolonc.2009.01.027
Hansen TB, Jensen TI, Clausen BH et al (2013) Natural RNA circles function as efficient microRNA sponges. Nature 495:384–388. https://doi.org/10.1038/nature11993
Hao Z, Fan W, Hao J et al (2016) Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv 23:874–881. https://doi.org/10.3109/10717544.2014.920059
Harrington KJ, Lewanski C, Northcote AD et al (2001) Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer Oxf Engl 37:2015–2022
Heitz F, Morris MC, Divita G (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157:195–206. https://doi.org/10.1111/j.1476-5381.2009.00057.x
Hiraki M, Nishimura J, Takahashi H et al (2015) Concurrent targeting of KRAS and AKT by MiR-4689 is a novel treatment against mutant KRAS colorectal cancer. Mol Ther Nucleic Acids 4:e231. https://doi.org/10.1038/mtna.2015.5
Höbel S, Aigner A (2013) Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5:484–501. https://doi.org/10.1002/wnan.1228
Holtkamp S, Kreiter S, Selmi A et al (2006) Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108:4009–4017. https://doi.org/10.1182/blood-2006-04-015024
Hope MJ (2014) Enhancing siRNA delivery by employing lipid nanoparticles. Ther Deliv 5:663–673. https://doi.org/10.4155/tde.14.37
Hu QL, Jiang QY, Jin X et al (2013) Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34:2265–2276. https://doi.org/10.1016/j.biomaterials.2012.12.016
Huang X, Yuan T, Liang M et al (2015) Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67:33–41. https://doi.org/10.1016/j.eururo.2014.07.035
Immordino ML, Dosio F, Cattel L (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
Janssen HLA, Reesink HW, Lawitz EJ et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685–1694. https://doi.org/10.1056/NEJMoa1209026
Jemielity J, Fowler T, Zuberek J et al (2003) Novel “anti-reverse” cap analogs with superior translational properties. RNA 9:1108–1122
Jiang M, Huang O, Xie Z et al (2014) A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 87:254–283. https://doi.org/10.1016/j.bcp.2013.10.020
Johnston SR, Gore ME (2001) Caelyx: phase II studies in ovarian cancer. Eur J Cancer Oxf Engl 1990(37 Suppl 9):S8–S14
Judge A, MacLachlan I (2008) Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19:111–124. https://doi.org/10.1089/hum.2007.179
Juliano R, Alam MR, Dixit V, Kang H (2008) Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36:4158–4171. https://doi.org/10.1093/nar/gkn342
Kalimutho M, Del Vecchio Blanco G, Di Cecilia S et al (2011) Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 46:1391–1402. https://doi.org/10.1007/s00535-011-0456-0
Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG (2012) Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther J Am Soc Gene Ther 20:513–524. https://doi.org/10.1038/mt.2011.294
Kawakami S, Yamashita F, Nishikawa M et al (1998) Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes. Biochem Biophys Res Commun 252:78–83. https://doi.org/10.1006/bbrc.1998.9602
Kawamata T, Seitz H, Tomari Y (2009) Structural determinants of miRNAs for RISC loading and slicer-independent unwinding. Nat Struct Mol Biol 16:953–960. https://doi.org/10.1038/nsmb.1630
Kawasaki H, Taira K (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 31:700–707
Keklikoglou I, Hosaka K, Bender C et al (2015) MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene 34:4867–4878. https://doi.org/10.1038/onc.2014.408
Khatri N, Rathi M, Baradia D et al (2012) In vivo delivery aspects of miRNA, shRNA and siRNA. Crit Rev Ther Drug Carrier Syst 29:487–527
Khvorova A, Lescoute A, Westhof E, Jayasena SD (2003) Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nat Struct Biol 10:708–712. https://doi.org/10.1038/nsb959
Kievit FM, Zhang M (2011) Surface engineering of iron oxide nanoparticles for targeted cancer therapy. Acc Chem Res 44:853–862. https://doi.org/10.1021/ar2000277
Kievit FM, Veiseh O, Bhattarai N et al (2009) PEI-PEG-chitosan copolymer coated iron oxide nanoparticles for safe gene delivery: synthesis, complexation, and transfection. Adv Funct Mater 19:2244–2251. https://doi.org/10.1002/adfm.200801844
Kim J-K, Choi S-H, Kim C-O et al (2003) Enhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency. J Pharm Pharmacol 55:453–460. https://doi.org/10.1211/002235702928
Kim C, Shah BP, Subramaniam P, Lee K-B (2011) Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. Mol Pharm 8:1955–1961. https://doi.org/10.1021/mp100460h
Koga Y, Yasunaga M, Takahashi A et al (2010) MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 3:1435–1442. https://doi.org/10.1158/1940-6207.CAPR-10-0036
Kolb G, Reigadas S, Castanotto D et al (2006) Endogenous expression of an anti-TAR aptamer reduces HIV-1 replication. RNA Biol 3:150–156
Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140. https://doi.org/10.1038/nrd3625
Kosaka N, Izumi H, Sekine K, Ochiya T (2010) microRNA as a new immune-regulatory agent in breast milk. Silence 1:7. https://doi.org/10.1186/1758-907X-1-7
Kuhn AN, Diken M, Kreiter S et al (2010) Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther 17:961–971. https://doi.org/10.1038/gt.2010.52
Kuhn AN, Beiβert T, Simon P et al (2012) mRNA as a versatile tool for exogenous protein expression. Curr Gene Ther 12:347–361
Kundu SK, Sharma AR, Lee S-S et al (2014) Recent trends of polymer mediated liposomal gene delivery system. Biomed Res Int 2014. https://doi.org/10.1155/2014/934605
Lee SH, Castagner B, Leroux J-C (2013) Is there a future for cell-penetrating peptides in oligonucleotide delivery? Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV 85:5–11. https://doi.org/10.1016/j.ejpb.2013.03.021
Lee B, Mazar J, Aftab MN et al (2014) Long noncoding RNAs as putative biomarkers for prostate cancer detection. J Mol Diagn 16:615–626. https://doi.org/10.1016/j.jmoldx.2014.06.009
Lewis H, Lance R, Troyer D et al (2014) miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration. Cell Cycle Georget Tex 13:227–239. https://doi.org/10.4161/cc.26984
Li Z, Rana TM (2014) Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 13:622–638. https://doi.org/10.1038/nrd4359
Ling H, Girnita L, Buda O, Calin GA (2017) Non-coding RNAs: the cancer genome dark matter that matters! Clin Chem Lab Med 55:705–714. https://doi.org/10.1515/cclm-2016-0740
Link A, Becker V, Goel A et al (2012) Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One 7:e42933. https://doi.org/10.1371/journal.pone.0042933
Liu Y, Wang J (2016) Therapeutic potentials of noncoding RNAs: targeted delivery of ncRNAs in cancer cells. Adv Exp Med Biol 927:429–458. https://doi.org/10.1007/978-981-10-1498-7_16
Liu H, Rajasekaran AK, Moy P et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58:4055–4060
Liu J, Sun H, Wang X et al (2014) Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer. Int J Mol Sci 15:758–773. https://doi.org/10.3390/ijms15010758
Lünse CE, Michlewski G, Hopp CS et al (2010) An aptamer targeting the apical-loop domain modulates pri-miRNA processing. Angew Chem Int Ed Eng 49:4674–4677. https://doi.org/10.1002/anie.200906919
Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029–4033
Ma Y, Yang Y, Wang F et al (2016) Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α. Gut 65:1494–1504. https://doi.org/10.1136/gutjnl-2014-308392
Mahmoudi M, Laurent S, Shokrgozar MA, Hosseinkhani M (2011) Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell “vision” versus physicochemical properties of nanoparticles. ACS Nano 5:7263–7276. https://doi.org/10.1021/nn2021088
Mallick S, Choi JS (2014) Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J Nanosci Nanotechnol 14:755–765
Manterola L, Guruceaga E, Gállego Pérez-Larraya J et al (2014) A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro-Oncol 16:520–527. https://doi.org/10.1093/neuonc/not218
Martin SA, Paoletti E, Moss B (1975) Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem 250:9322–9329
Mayer G, Raddatz M-SL, Grunwald JD, Famulok M (2007) RNA ligands that distinguish metabolite-induced conformations in the TPP riboswitch. Angew Chem Int Ed Eng 46:557–560. https://doi.org/10.1002/anie.200603166
McClorey G, Wood MJ (2015) An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr Opin Pharmacol 24:52–58. https://doi.org/10.1016/j.coph.2015.07.005
Meister G, Landthaler M, Dorsett Y, Tuschl T (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544–550
Metselaar JM, Bruin P, de Boer LWT et al (2003) A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem 14:1156–1164. https://doi.org/10.1021/bc0340363
Migault M, Donnou-Fournet E, Galibert M-D, Gilot D (2017) Definition and identification of small RNA sponges: focus on miRNA sequestration. Methods 117:35–47. https://doi.org/10.1016/j.ymeth.2016.11.012
Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518. https://doi.org/10.1073/pnas.0804549105
Mlcochova H, Hezova R, Stanik M, Slaby O (2014) Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 32:41.e1–41.e9. https://doi.org/10.1016/j.urolonc.2013.04.011
Mulhbacher J, St-Pierre P, Lafontaine DA (2010) Therapeutic applications of ribozymes and riboswitches. Curr Opin Pharmacol 10:551–556. https://doi.org/10.1016/j.coph.2010.07.002
Nchinda G, Uberla K, Zschörnig O (2002) Characterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition. BMC Biotechnol 2:12
O’Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin Breast Cancer 4:318–328
Obad S, dos Santos CO, Petri A et al (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371–378. https://doi.org/10.1038/ng.786
Ochiya T, Takahama Y, Nagahara S et al (1999) New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet. Nat Med 5:707–710. https://doi.org/10.1038/9560
Ochiya T, Nagahara S, Sano A et al (2001) Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther 1:31–52
Ogata-Kawata H, Izumiya M, Kurioka D et al (2014) Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 9:e92921. https://doi.org/10.1371/journal.pone.0092921
Otaegi G, Pollock A, Sun T (2011) An optimized sponge for microRNA miR-9 affects spinal motor neuron development in vivo. Front Neurosci 5:146. https://doi.org/10.3389/fnins.2011.00146
Park NJ, Zhou H, Elashoff D et al (2009) Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res Off J Am Assoc Cancer Res 15:5473–5477. https://doi.org/10.1158/1078-0432.CCR-09-0736
Patil ML, Zhang M, Betigeri S et al (2008) Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem 19:1396–1403. https://doi.org/10.1021/bc8000722
Patil ML, Zhang M, Taratula O et al (2009) Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 10:258–266. https://doi.org/10.1021/bm8009973
Peer D, Zhu P, Carman CV et al (2007) Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A 104:4095–4100. https://doi.org/10.1073/pnas.0608491104
Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CMP (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18:282–289. https://doi.org/10.1016/j.drudis.2012.10.002
Petersen M, Wengel J (2003) LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 21:74–81. https://doi.org/10.1016/S0167-7799(02)00038-0
Petersen KE, Manangon E, Hood JL et al (2014) A review of exosome separation techniques and characterization of B16-F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM. Anal Bioanal Chem 406:7855–7866. https://doi.org/10.1007/s00216-014-8040-0
Pickard MR, Williams GT (2014) Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast Cancer Res Treat 145:359–370. https://doi.org/10.1007/s10549-014-2974-y
Poliseno L, Salmena L, Zhang J et al (2010) A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465:1033–1038. https://doi.org/10.1038/nature09144
Pramanik D, Campbell NR, Karikari C et al (2011) Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10:1470–1480. https://doi.org/10.1158/1535-7163.MCT-11-0152
Que R, Ding G, Chen J, Cao L (2013) Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol 11:219. https://doi.org/10.1186/1477-7819-11-219
Raal FJ, Santos RD, Blom DJ et al (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998–1006. https://doi.org/10.1016/S0140-6736(10)60284-X
Raza U, Zhang JD, Sahin O (2014) MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med Berl Ger 92:321–336. https://doi.org/10.1007/s00109-014-1129-2
Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, Wei M, Xu C, Wu C, Zhang Z, Xu G, Liu Z, Hou J, Huang J, Sun Y (2013) Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 49(13):2949–2959
Rivas A, Burzio V, Landerer E et al (2012) Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer. BMC Urol 12:37. https://doi.org/10.1186/1471-2490-12-37
Rothschild SI (2014) microRNA therapies in cancer. Mol Cell Ther 2:7. https://doi.org/10.1186/2052-8426-2-7
Sahin U, Karikó K, Türeci Ö (2014) mRNA-based therapeutics--developing a new class of drugs. Nat Rev Drug Discov 13:759–780. https://doi.org/10.1038/nrd4278
Sarkar FH, Li Y, Wang Z et al (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 13:57–66. https://doi.org/10.1016/j.drup.2010.02.001
Schmidinger M, Wenzel C, Locker GJ et al (2001) Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 85:1850–1852. https://doi.org/10.1054/bjoc.2001.2149
Schwarzenbach H (2015) The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer. Expert Rev Mol Diagn 15:1159–1169. https://doi.org/10.1586/14737159.2015.1069183
Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11:145–156. https://doi.org/10.1038/nrclinonc.2014.5
Scognamiglio I, Di Martino MT, Campani V, et al (2014) Transferrin-conjugated SNALPs encapsulating 2’-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int 2014:217365. doi: https://doi.org/10.1155/2014/217365
Scott WG (2007) Ribozymes. Curr Opin Struct Biol 17:280–286. https://doi.org/10.1016/j.sbi.2007.05.003
Semple SC, Klimuk SK, Harasym TO et al (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510:152–166
Semple SC, Akinc A, Chen J et al (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172–176. https://doi.org/10.1038/nbt.1602
Shen T, Han M, Wei G, Ni T (2015) An intriguing RNA species--perspectives of circularized RNA. Protein Cell 6:871–880. https://doi.org/10.1007/s13238-015-0202-0
Simpson RJ, Lim JW, Moritz RL, Mathivanan S (2009) Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics 6:267–283. https://doi.org/10.1586/epr.09.17
Singha K, Namgung R, Kim WJ (2011) Polymers in small-interfering RNA delivery. Nucleic Acid Ther 21:133–147. https://doi.org/10.1089/nat.2011.0293
Sitharaman B (2016) Nanobiomaterials handbook. CRC Press, Boca Raton
Snead NM, Rossi JJ (2010) Biogenesis and function of endogenous and exogenous siRNAs. Wiley Interdiscip Rev RNA 1:117–131. https://doi.org/10.1002/wrna.14
Snøve O, Holen T (2004) Many commonly used siRNAs risk off-target activity. Biochem Biophys Res Commun 319:256–263. https://doi.org/10.1016/j.bbrc.2004.04.175
Song E, Zhu P, Lee S-K et al (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23:709–717. https://doi.org/10.1038/nbt1101
Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173–178. https://doi.org/10.1038/nature03121
Srinageshwar B, Peruzzaro S, Andrews M et al (2017) PAMAM dendrimers cross the blood-brain barrier when administered through the carotid artery in C57BL/6J mice. Int J Mol Sci 18. https://doi.org/10.3390/ijms18030628
Stanton R, Sciabola S, Salatto C et al (2012) Chemical modification study of antisense gapmers. Nucleic Acid Ther 22:344–359. https://doi.org/10.1089/nat.2012.0366
Stepinski J, Waddell C, Stolarski R et al (2001) Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3’-O-methyl)GpppG and 7-methyl (3’-deoxy)GpppG. RNA 7:1486–1495
Subramanian N, Kanwar JR, Kanwar RK, Krishnakumar S (2015) Blocking the maturation of OncomiRNAs using pri-miRNA-17∼92 aptamer in retinoblastoma. Nucleic Acid Ther 25:47–52. https://doi.org/10.1089/nat.2014.0507
Sugimachi K, Matsumura T, Hirata H et al (2015) Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 112:532–538. https://doi.org/10.1038/bjc.2014.621
Sullenger BA, Nair S (2016) From the RNA world to the clinic. Science 352:1417–1420. https://doi.org/10.1126/science.aad8709
Sun Z, Song X, Li X et al (2014) In vivo multimodality imaging of miRNA-16 iron nanoparticle reversing drug resistance to chemotherapy in a mouse gastric cancer model. Nanoscale 6:14343–14353. https://doi.org/10.1039/c4nr03003f
Takagi S, Nakajima M, Mohri T, Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674–9680. https://doi.org/10.1074/jbc.M709382200
Tanaka Y, Kamohara H, Kinoshita K et al (2013) Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer 119:1159–1167. https://doi.org/10.1002/cncr.27895
Tang Y, Li Y-B, Wang B, Lin R-Y, van Dongen M, Zurcher DM, Gu X-Y, Holl MMB, Liu G, Qi R (2012) Efficient siRNA delivery and intramuscular gene silencing using PEG-Modified PAMAM dendrimers. Mol Pharm 9(6):1812–1821
Tang H, Wu Z, Zhang J, Su B (2013) Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep 7:761–766. https://doi.org/10.3892/mmr.2012.1254
Tantai J, Hu D, Yang Y, Geng J (2015) Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Int J Clin Exp Pathol 8:7887–7895
Tay FC, Lim JK, Zhu H et al (2015) Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv Drug Deliv Rev 81:117–127. https://doi.org/10.1016/j.addr.2014.05.010
Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110:13–21. https://doi.org/10.1016/j.ygyno.2008.04.033
Taylor DD, Shah S (2015) Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods 87:3–10. https://doi.org/10.1016/j.ymeth.2015.02.019
Tedeschi L, Lande C, Cecchettini A, Citti L (2009) Hammerhead ribozymes in therapeutic target discovery and validation. Drug Discov Today 14:776–783. https://doi.org/10.1016/j.drudis.2009.05.003
Terasawa K, Shimizu K, Tsujimoto G (2011) Synthetic pre-miRNA-based shRNA as potent RNAi triggers. J Nucleic Acids 2011:131579. https://doi.org/10.4061/2011/131579
Thiel KW, Hernandez LI, Dassie JP et al (2012) Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40:6319–6337. https://doi.org/10.1093/nar/gks294
Toloue MM, Ford LP (2011) Antibody targeted siRNA delivery. Methods Mol Biol 764:123–139. https://doi.org/10.1007/978-1-61779-188-8_8
Tripathi V, Ellis JD, Shen Z et al (2010) The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 39:925–938. https://doi.org/10.1016/j.molcel.2010.08.011
Tsuchiya Y, Nakajima M, Takagi S et al (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 66:9090–9098. https://doi.org/10.1158/0008-5472.CAN-06-1403
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510
Turchinovich A, Samatov TR, Tonevitsky AG, Burwinkel B (2013) Circulating miRNAs: cell-cell communication function? Front Genet 4:119. https://doi.org/10.3389/fgene.2013.00119
Turturici G, Tinnirello R, Sconzo G, Geraci F (2014) Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Phys Cell Phys 306:C621–C633. https://doi.org/10.1152/ajpcell.00228.2013
Vaksman O, Tropé C, Davidson B, Reich R (2014) Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 35:2113–2120. https://doi.org/10.1093/carcin/bgu130
Valadi H, Ekström K, Bossios A et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. https://doi.org/10.1038/ncb1596
Vickers KC, Palmisano BT, Shoucri BM et al (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433. https://doi.org/10.1038/ncb2210
Wang X, Wang Y, Chen ZG, Shin DM (2009) Advances of cancer therapy by nanotechnology. Cancer Res Treat 41:1–11. https://doi.org/10.4143/crt.2009.41.1.1
Wang J, Chen Y, Chen B et al (2010a) Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. Int J Nanomedicine 5:861–866. https://doi.org/10.2147/IJN.S13662
Wang K, Zhang S, Weber J et al (2010b) Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 38:7248–7259. https://doi.org/10.1093/nar/gkq601
Wang F, Li T, Zhang B et al (2013a) MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun 434:688–694. https://doi.org/10.1016/j.bbrc.2013.04.010
Wang Y, Xu Z, Jiang J et al (2013b) Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell 25:69–80. https://doi.org/10.1016/j.devcel.2013.03.002
Wang F, Ren S, Chen R et al (2014a) Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget 5:11091–11102. https://doi.org/10.18632/oncotarget.2691
Wang H, Hou L, Li A et al (2014b) Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int 2014:864894. https://doi.org/10.1155/2014/864894
Wang J, Zhou Y, Lu J et al (2014c) Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol Northwood Lond Engl 31:148. https://doi.org/10.1007/s12032-014-0148-8
Wang Y, Zhang D, Wu K et al (2014d) Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol 34:3182–3193. https://doi.org/10.1128/MCB.01580-13
Weber JA, Baxter DH, Zhang S et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741. https://doi.org/10.1373/clinchem.2010.147405
Wolff JA, Malone RW, Williams P et al (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468
Wolfrum C, Shi S, Jayaprakash KN et al (2007) Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25:1149–1157. https://doi.org/10.1038/nbt1339
Wollina U, Dummer R, Brockmeyer NH et al (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:993–1001. https://doi.org/10.1002/cncr.11593
Wu X, Yamamoto H, Nakanishi H et al (2015) Innovative delivery of siRNA to solid tumors by super carbonate apatite. PLoS One 10:e0116022. https://doi.org/10.1371/journal.pone.0116022
Xiao Z, Li CH, Chan SL et al (2014) A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res 74:6236–6247. https://doi.org/10.1158/0008-5472.CAN-14-0855
Xie J, Huang J, Li X et al (2009) Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem 16:1278–1294
Xie Z, Chen G, Zhang X et al (2013) Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One 8:e57502. https://doi.org/10.1371/journal.pone.0057502
Xiong X-D, Ren X, Cai M-Y et al (2016) Long non-coding RNAs: an emerging powerhouse in the battle between life and death of tumor cells. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 26:28–42. https://doi.org/10.1016/j.drup.2016.04.001
Xue HY, Guo P, Wen W-C, Wong HL (2015) Lipid-based nanocarriers for RNA delivery. Curr Pharm Des 21:3140–3147
Yamada Y, Enokida H, Kojima S et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529. https://doi.org/10.1111/j.1349-7006.2010.01816.x
Young DD, Connelly CM, Grohmann C, Deiters A (2010) Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J Am Chem Soc 132:7976–7981. https://doi.org/10.1021/ja910275u
Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75:280–284
Zelphati O, Szoka FC (1996) Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A 93:11493–11498
Zhang J-S, Liu F, Huang L (2005) Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 57:689–698. https://doi.org/10.1016/j.addr.2004.12.004
Zhang Z, Hao H, Zhang C et al (2012) Evaluation of novel gene UCA1 as a tumor biomarker for the detection of bladder cancer. Zhonghua Yi Xue Za Zhi 92:384–387
Zhang Y, Wang Z, Gemeinhart RA (2013) Progress in microRNA delivery. J Control Release 172:962–974. https://doi.org/10.1016/j.jconrel.2013.09.015
Zhang W, Ren S-C, Shi X-L et al (2015) A novel urinary long non-coding RNA transcript improves diagnostic accuracy in patients undergoing prostate biopsy. Prostate 75:653–661. https://doi.org/10.1002/pros.22949
Zhu H, Wu H, Liu X et al (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76:582–588. https://doi.org/10.1016/j.bcp.2008.06.007
Ziemniak M, Strenkowska M, Kowalska J, Jemielity J (2013) Potential therapeutic applications of RNA cap analogs. Future Med Chem 5:1141–1172. https://doi.org/10.4155/fmc.13.96
Zinckgraf JW, Silbart LK (2003) Modulating gene expression using DNA vaccines with different 3’-UTRs influences antibody titer, seroconversion and cytokine profiles. Vaccine 21:1640–1649
Zuidam NJ, Barenholz Y (1998) Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. Biochim Biophys Acta 1368:115–128
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Arora, M., Kaul, D. (2018). RNome in Cancer Therapy. In: Cancer RNome: Nature & Evolution. Springer, Singapore. https://doi.org/10.1007/978-981-13-1568-8_4
Download citation
DOI: https://doi.org/10.1007/978-981-13-1568-8_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-1567-1
Online ISBN: 978-981-13-1568-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)